Umbilical cord mesenchymal stem cell injections for moderate to severe diabetic peripheral neuropathy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, controlled Phase 2 trial compares three injections of human umbilical cord mesenchymal stem cells plus conventional therapy to conventional therapy alone in adults with moderate to severe diabetic peripheral neuropathy. The experimental group receives hUC-MSC injections on Day 0, Day 7, and Day 28 while both groups continue standard medical care. The primary endpoint is change in the Toronto Clinical Scoring System (TCSS) score at Week 24, with safety monitored throughout and extended follow-up to Week 104 for long-term safety data. Participants must meet neurophysiological criteria for neuropathy and will attend regular visits for clinical and nerve-conduction assessments.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Males or females aged 18-80 years;
2. Meeting the 2023 ADA diagnostic criteria for type 2 diabetes;
3. Presence of symptoms and signs of diabetic neuropathy in lower extremities:

   For symptomatic patients: At least one abnormal finding among ankle reflex, pinprick sensation, vibration sense, pressure perception, or temperature sensation, accompanied by clinical symptoms (e.g., symmetric lower limb numbness, pain, or tingling); For asymptomatic patients: At least two abnormal findings in the above five examinations;
4. Confirmed neurophysiological dysfunction:

   Reduced nerve conduction velocity (≥2 standard deviations) in at least one lower extremity nerve (common peroneal, posterior tibial, or deep peroneal nerve), with or without decreased amplitude;

   Moderate to severe neuropathy severity:
5. Toronto Clinical Scoring System (TCSS) score ≥9;
6. Inadequate response to conventional therapy: Persistent symptoms (reduction of TCSS score \<2 points from baseline) despite ≥3 months of conventinal treatment;
7. Capacity to understand and voluntarily complete all study procedures and interventions, with signed informed consent.

Exclusion Criteria:

1. Non-diabetic neuropathy or pain conditions in lower limbs that may confound DPN assessment per investigator's judgment;
2. Poorly controlled diabetes (HbA1c \>12%);
3. Severe hematological, hepatic, or renal dysfunction, meeting any of the following laboratory criteria:

   Hematology: Neutrophils \<1.5×10⁹/L, platelets \<90×10⁹/L, or hemoglobin \<80 g/L; Liver function: ALT or AST \>3× upper limit of normal (ULN), or total bilirubin \>1.5× ULN; Renal function: eGFR \<30 mL/min/1.73m² (calculated by MDRD formula) or requiring renal replacement therapy; Creatine kinase \>2× ULN;
4. Known allergy to stem cells, stem cell-derived products, or components of stem cell preparations;
5. Current use of prohibited medications within 5 half-lives prior to enrollment (may be reconsidered after ≥5 half-lives washout);
6. Uncontrolled systemic diseases, including but not limited to: Severe uncontrolled systemic infections (bacterial, fungal, or viral); Severe autoimmune disorders; Hematological diseases; Heart failure (NYHA class ≥III);
7. Clinically significant arrhythmia on 12-lead ECG;
8. Conditions requiring amputation (e.g., severe diabetic foot or lower limb ulcers) that preclude local stem cell injection;
9. Other diseases unsuitable for trial participation (e.g., active malignancy, cognitive impairment, depression, or psychiatric disorders);
10. Participation in any interventional clinical trial within 3 months prior to screening;
11. Pregnancy, lactation, or planning pregnancy within 2 years;
12. Any other condition deemed by the investigator to compromise trial suitability.

Where it's running

• Southwest Hospital
  Chongqing, Chongqing Municipality, China Recruiting

Study contacts

• Study coordinator: Min Long
• Email: longmin_casper@163.com
• Phone: +862368765431

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Benfotiamine vs. B1-6-12 for diabetic nerve pain

  This trial tests whether benfotiamine can better reduce sensory symptoms, numbness, and pain in adults with diabetic peripheral neuropathy compared to a vitamin B1-6-12 formulation.

  Recruiting Phase 4 Thammasat University · Pathumthani, Bangkok · NCT07708233

• Tai Chi versus Modified-Otago exercises for pain, balance, and walking in diabetic peripheral neuropathy

  This trial will test whether Tai Chi or Modified-Otago exercises better reduce pain and improve balance and movement in people with diabetic peripheral neuropathy.

  Recruiting Riphah International University · Lahore, Punjab Province · NCT07078565

• Trimetazidine to help diabetic neuropathy symptoms and endothelin-1 levels

  This study tests whether taking trimetazidine can improve symptoms for adults with type 2 diabetes and diabetic peripheral neuropathy.

  Recruiting Phase 1/2 Ain Shams University · Cairo · NCT07794475

• Cannabidiol to treat pain from diabetic peripheral neuropathy (pilot)

  This pilot tests whether daily oral cannabidiol or full‑spectrum CBD tinctures reduce pain in adults 40–70 with mild-to-moderate diabetic peripheral neuropathy.

  Recruiting Phase 1/2 Florida A&M University · Tallahassee, Florida · NCT07298408

• Sensory testing to guide medication choice for painful peripheral neuropathy

  This will try to see if sensory testing can predict which people with painful peripheral neuropathy get more pain relief from duloxetine or pregabalin than from placebo.

  Recruiting at 7 sites Phase 2 University of Rochester · Boston, Massachusetts and 6 other locations · NCT06614322

• Effects of perturbation-based balance training vs conventional balance training for reactive stepping in adults with diabetic nerve damage

  A 40-person study will test whether adding perturbation-based balance training helps adults with diabetic peripheral neuropathy react better to balance threats compared with standard balance training.

  Recruiting Lahore University of Biological and Applied Sciences · Lahore, Punjab Province · NCT07902297

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.